Miklos Molnar, MD
Nephrology · Memphis, TNNPI 1104299304
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,414 of the $12,144 with a category attached, or 77.5%. 7 manufacturers reported payments, led by Novartis at 58.9% of the total. Reporting peaked in 2024 at $7,810 and has fallen 50.1% since, to $3,900 in 2025.
Across 17 payments — averaging $714.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Apellis Pharmaceuticals, Inc.$4K
- One Lambda, Inc.$517
- Sanofi-aventis U.S. LLC$333
- Amgen$132
- AstraZeneca$110
- plus $90 from 1 others
What the payments were for
- Consulting fees$9,41478%
- Speaking & faculty fees$4504%
- Travel & lodging$8397%
- Food & beverage$1,44112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $7,150 |
| Apellis Pharmaceuticals, Inc. | 2 | $3,811 |
| One Lambda, Inc. | 2 | $517 |
| Sanofi-aventis U.S. LLC | 3 | $333 |
| Amgen(2 entities) | 2 | $132 |
| AstraZeneca | 1 | $110 |
| Sanofi | 1 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Empaveli$3,811
- THYMOGLOBULIN$242
How this compares
$12,144 in reported general payments places this provider in the 85th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 23 | $15,726 |
| Valganciclovir Hcl | 23 | $6,221 |
| Cinacalcet Hcl | 11 | $969 |
| Prednisone | 71 | $408 |
| Carvedilol | 58 | $271 |
| Atorvastatin Calcium | 51 | $269 |
| Famotidine | 22 | $163 |
| Amlodipine Besylate | 36 | $161 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $135 |
| Tamsulosin Hcl | 15 | $121 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Memphis
- Omar HamzeMemphis$90K
- Omar DavisMemphis$70K
- Natarsha GrantMemphis$53K
- Marc StegmanMemphis$41K
- Robert CanadaMemphis$20K
- Minesh PathakMemphis$14K
- Wael HusseinMemphis$10K
- Sanjeev MittalMemphis$9K
- Vasanthi BalaramanMemphis$8K
- Mark Abi NaderMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.